KYMERA THERAPEUTICS, INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 28 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $3M | ↓-61.2% | — | — | — |
| 2025-09-30 | $3M | ↓-26.1% | $-82M | ↓-31.5% | -3347.4% |
| 2025-06-30 | $11M | ↓-55.3% | $-77M | ↓-82.1% | -736.8% |
| 2025-03-31 | $22M | ↑+114.8% | $-66M | ↓-35.1% | -336.8% |
| 2024-12-31 | $7M | ↓-84.6% | — | — | — |
| 2024-09-30 | $4M | ↓-20.9% | $-62M | ↓-18.2% | -1927.9% |
| 2024-06-30 | $26M | ↑+55.3% | $-42M | ↓-8.4% | -198.5% |
| 2024-03-31 | $10M | ↑+8.7% | $-49M | ↓-18.6% | -562.2% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$3M
↓-61.2% -$5M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
KYMR Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyKYMR Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics